Fasting glucose is the last marker to move
Insulin resistance refers to a state where cells respond less well to insulin, and where the pancreas compensates by producing more of it. As long as compensation holds, glucose stays normal. That is why a blood panel can reassure a person whose metabolism has been drifting for years.
A meta-analysis of 65 studies and 516,325 participants compared the strength of three markers for predicting cardiovascular events in adults without diabetes. Per standard deviation increase, the relative risk of coronary heart disease was 1.21 for fasting glucose, 1.04 for insulin alone, a non significant figure, and 1.46 for HOMA-IR.
HOMA-IR, which combines fasting glucose and insulin, therefore predicts better than either taken alone, and better than the glucose everyone looks at. It also showed zero heterogeneity between studies, where glucose reached 62%, which means its signal reproduces from one cohort to the next.
The same number does not carry the same weight depending on context
A national analysis published in 2022 measured the cardiovascular risk associated with HOMA-IR according to baseline glycemic status. In people with normal glucose tolerance, the highest quartile of HOMA-IR was not associated with excess risk, hazard ratio 1.03 with an interval crossing 1.
In people with prediabetes, the same quartile gave a hazard ratio of 1.23, and in diabetics 1.61, with a statistically significant interaction. In other words, insulin resistance becomes dangerous when it comes with a glucose level that is starting to give way.
The detail guides practice. A high HOMA-IR in a person whose glucose is strictly normal is a signal about trajectory, not an emergency. The same number in a person with prediabetes, especially with associated obesity, points to a situation where coaching has measurable value.
Prediabetes multiplies risk by six, not by two
A meta-analysis of 59 studies compared the onset of type 2 diabetes in people with prediabetes and in normoglycemic people. The pooled relative risk is 5.88, confidence interval 5.02 to 6.89.
Annual incidence, however, varies enormously, from 2.20 to 212.15 per 1,000 person-years depending on the study, with 96.6% heterogeneity. That spread comes from the criteria used to define prediabetes and from the populations studied: combining high HbA1c with impaired fasting glucose carried the highest risk.
For a professional, the consequence is simple. Announcing an individual risk percentage from these data makes no sense, the gap between studies is a factor of one hundred. Saying that prediabetes multiplies risk by about six, and that this risk depends on how it was defined, is accurate.
Lifestyle beats metformin, and we know by how much
The Diabetes Prevention Program remains the reference trial. It allocated 3,234 non diabetic people with high fasting glucose, mean age 51 and mean body mass index 34, between placebo, metformin and a lifestyle program aiming for 7% weight loss and 150 minutes of activity per week.
Over a mean follow-up of 2.8 years, diabetes incidence was 11.0, 7.8 and 4.8 cases per 100 person-years. Lifestyle reduced incidence by 58%, metformin by 31%. To prevent one case of diabetes over three years, 6.9 people had to be coached through lifestyle, against 13.9 on metformin. The Finnish trial published a year earlier found exactly the same 58% reduction with a mean weight loss of only 4.2 kg in the first year.
These results hold over time, while attenuating. At fifteen years, the incidence reduction fell to 27% for lifestyle and 18% for metformin. At twenty one years, the hazard ratio was 0.76 and 0.83, a median gain in diabetes free survival of 3.5 and 2.5 years. The curves separate mainly in the first three years, which points to the window where coaching matters most.
Weight loss reverses part of the picture
A dose-response meta-analysis of 44 trials and 14,742 people with prediabetes, with mean weight losses from 1% to 9%, quantified the two outcomes that matter in coaching. Return to normal glucose increased by 11 cases per 100 participants, relative risk 1.51. Progression to diabetes decreased by 8 cases per 100, relative risk 0.59.
No significant difference appeared between types of intervention or according to their duration. It is not the method that decides, it is the size of the weight loss obtained and maintained.
The DiRECT trial shows it beyond prediabetes, in 306 people with recent diabetes followed in general practice. Remission at twelve months reached 46% in the intervention group against 4% in the control group, and it followed weight lost almost linearly: no remission among those who gained weight, 7% between 0 and 5 kg lost, 34% between 5 and 10 kg, 57% between 10 and 15 kg, and 86% beyond 15 kg.
Exercise acts on the marker without going through the scale
A meta-analysis of 78 reports and 2,509 people measured the effect of exercise programs on insulin sensitivity in healthy adults. The between group effect size after intervention was 0.38, confidence interval 0.25 to 0.51, with zero heterogeneity.
The authors translate that figure usefully for consultation: it corresponds to a mean fasting insulin of 6.8 mU/L in the trained group against 7.9 mU/L in controls. The exploratory analysis found no modality superior to the others according to exercise type or participant characteristics.
That is a lever of its own, because it does not depend on weight loss. In a person whose weight no longer moves, activity keeps acting on the marker. Endurance work and strength training both contribute, and a blood panel interpreted rigorously makes it possible to follow the effect without multiplying blood draws.
Sources
- 1.Gast KB, et al. Insulin resistance and risk of incident cardiovascular events in adults without diabetes: meta-analysis. PLoS One. 2012.
- 2.Wang T, et al. Association Between Insulin Resistance and Cardiovascular Disease Risk Varies According to Glucose Tolerance Status: A Nationwide Prospective Cohort Study. Diabetes Care. 2022.
- 3.Xu XY, et al. The relative risk of developing type 2 diabetes among individuals with prediabetes compared with individuals with normoglycaemia: Meta-analysis and meta-regression. J Adv Nurs. 2020.
- 4.Knowler WC, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002.
- 5.Tuomilehto J, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001.
- 6.Diabetes Prevention Program Research Group. Long-term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15-year follow-up: the Diabetes Prevention Program Outcomes Study. Lancet Diabetes Endocrinol. 2015.
- 7.Knowler WC, et al. Long-term effects and effect heterogeneity of lifestyle and metformin interventions on type 2 diabetes incidence over 21 years in the US Diabetes Prevention Program randomised clinical trial. Lancet Diabetes Endocrinol. 2025.
- 8.Jayedi A, et al. Efficacy of lifestyle weight loss interventions on regression to normoglycemia and progression to type 2 diabetes in individuals with prediabetes: a systematic review and pairwise and dose-response meta-analyses. Am J Clin Nutr. 2024.
- 9.Conn VS, et al. Insulin Sensitivity Following Exercise Interventions: Systematic Review and Meta-Analysis of Outcomes Among Healthy Adults. J Prim Care Community Health. 2014.
- 10.Lean ME, et al. Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial. Lancet. 2018.
Reading studies is one thing, turning them into a plan is another
The Longevity Practitioner certification teaches the method that turns this kind of data into an accompaniment decision: assess, prioritise, plan over 90 days, re-measure, and know when to hand over.
11 modules, €2,200. Enrol
Continue reading
Benjamin Sant
Co-founder of the School of Longevity
Cofounder of the School of Longevity with Tristan Maruyama. A former officer trained at Saint-Cyr from 2019 to 2022 and a coach since 2018, he has supported more than 4,000 people. He leads the School's editorial content with one constant principle: pass on only what can be situated, verified and applied seriously.
This article is published for information and education. It does not replace medical advice. For any personal health question, consult a healthcare professional.
